>>Signaling Pathways>> Microbiology & Virology>> Reverse Transcriptase>>R-10015

R-10015

Catalog No.GC65207

HIV 감염에 대한 광범위한 항바이러스 화합물인 R-10015는 LIMK(LIM domain kinase)의 강력하고 선택적인 억제제로 작용하고 인간 LIMK1에 대해 38nM의 IC50으로 ATP 결합 포켓에 결합합니다.

Products are for research use only. Not for human use. We do not sell to patients.

R-10015 Chemical Structure

Cas No.: 2097938-51-5

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$297.00
재고 있음
5mg
US$270.00
재고 있음
10mg
US$423.00
재고 있음
50mg
US$1,260.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

R-10015, a broad-spectrum antiviral compound for HIV infection, acts as a potent and selective inhibitor of LIM domain kinase (LIMK) and binds to the ATP-binding pocket, with an IC50 of 38 nM for human LIMK1[1].

R-10015 (100 μM; 0-4 hours) inhibits cofilin phosphorylation directly through blocking LIM kinase in CEM-SS T cells[1].R-10015 inhibits HIV-1 DNA synthesis, nuclear migration, and virion release[1].R-10015 inhibits multiple viruses, including Zaire ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venezuelan equine encephalitis virus (VEEV), and herpes simplex virus 1 (HSV-1) [1].

R-10015 (10 mg/kg; i.p.) displays none indication of toxicity. The result suggests the possibility of short-term use of LIMK inhibitors to block viral infections[1].

[1]. Yi F, et al. Discovery of Novel Small-Molecule Inhibitors of LIM Domain Kinase for Inhibiting HIV-1. J Virol. 2017 Jun 9;91(13). pii: e02418-16.

리뷰

Review for R-10015

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for R-10015

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.